Compare CLF & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLF | CRNX |
|---|---|---|
| Founded | 1847 | 2008 |
| Country | United States | United States |
| Employees | 25000 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 3.9B |
| IPO Year | 2006 | 2018 |
| Metric | CLF | CRNX |
|---|---|---|
| Price | $10.30 | $36.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $10.43 | ★ $76.75 |
| AVG Volume (30 Days) | ★ 17.0M | 1.3M |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,610,000,000.00 | $1,039,000.00 |
| Revenue This Year | $8.76 | $720.10 |
| Revenue Next Year | $2.64 | $184.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.63 | $25.83 |
| 52 Week High | $16.70 | $57.99 |
| Indicator | CLF | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 42.96 |
| Support Level | $9.94 | $33.19 |
| Resistance Level | $11.19 | $37.23 |
| Average True Range (ATR) | 0.45 | 2.32 |
| MACD | -0.01 | -0.33 |
| Stochastic Oscillator | 25.99 | 14.08 |
Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.